Celestia S. Higano
Fred Hutchinson Cancer Research Center
465 Papers
3.4K Citations
Celestia S. Higano is an academic researcher from Fred Hutchinson Cancer Research Center. The author has contributed to research in topics: Prostate cancer & Medicine. The author has an hindex of 78, co-authored 423 publications. Previous affiliations of Celestia S. Higano include United States Department of Veterans Affairs & Ohio State University.
Chat about Author
Papers
Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome
Debraj GuhaThakurta,Nadeem A. Sheikh,Li-Qun Fan,Harini Kandadi,T. Craig Meagher,Simon J. Hall,Philip W. Kantoff,Celestia S. Higano,Eric J. Small,Thomas A. Gardner,Kate Bailey,Tuyen Vu,Todd DeVries,James Boyd Whitmore,Mark W. Frohlich,James B. Trager,Charles G. Drake +16 more
TL;DR: Sipuleucel-T induced humoral antigen spread in patients with mCRPC and IgG responses were associated with improved OS in IMPACT, an immunotherapy for asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer.
Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial
Andrew J. Armstrong,Ping Lin,Bertrand Tombal,Fred Saad,Celestia S. Higano,Anthony M. Joshua,Teresa Parli,Brad Rosbrook,Steve van Os,Tomasz M. Beer +9 more
TL;DR: With >5 yr of follow-up, enzalutamide continued to demonstrate improved survival in patients with mCRPC despite crossover and multiple subsequent effective therapies, balanced against a slightly higher rate of fatal cardiovascular events.
Enzalutamide, apalutamide, or darolutamide: are apples or bananas best for patients?
TL;DR: Questions remain regarding patient selection for these agents, particularly concerning adverse effects, patient PSA doubling time, and cost and formulary considerations.
A first in human phase I study of AZD8186, a potent and selective inhibitor of PI3K in patients with advanced solid tumours as monotherapy and in combination with the dual mTORC1/2 inhibitor vistusertib (AZD2014) or abiraterone acetate.
Aaron R. Hansen,Geoffrey I. Shapiro,Khanh T. Do,Rajiv Kumar,Juan Martin-Liberal,Celestia S. Higano,Kari B. Wisinski,Emma Dean,Elisabeth I. Heath,Dana E. Rathkopf,Mark Linch,Simon T. Barry,Wolfram Brugger,Elza C. de Bruin,Steve Colebrook,Teresa Klinowska,Patrick D. Mitchell,Ganesh Moorthy,Johann S. de Bono,Lillian L. Siu +19 more
TL;DR: AzD8186 (AZD) exhibits significant anti-tumour activity in PTEN-deficient preclinical models, particularly when combined with anti-androgens or the dual mTORC1/2 inhibitor vistusertib as discussed by the authors.
SRRM4 Expression and the Loss of REST Activity May Promote the Emergence of the Neuroendocrine Phenotype in Castration-Resistant Prostate Cancer.
Xiaotun Zhang,Ilsa Coleman,Lisha G. Brown,Lawrence D. True,Lori Kollath,Jared M. Lucas,Hung-Ming Lam,Ruth Dumpit,Eva Corey,Lisly Chéry,Bryce Lakely,Celestia S. Higano,Bruce Montgomery,Martine Roudier,Paul H. Lange,Peter S. Nelson,Robert L. Vessella,Robert L. Vessella,Colm Morrissey +18 more
TL;DR: Metastatic neuroendocrine status can be heterogeneous in the same patient, the CRPC neuro endocrine molecular phenotype can be defined by CHGA+/SYP+ dual positivity, and the splicing of REST by SRRM4 could promote the neuroendsocrine phenotype in CRPC.